Leanne Budde, MD
Medical Oncology · Lawrenceburg, INNPI 1164415329
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,518 of the $2,813 with a category attached, or 89.5%. It is spread thinly across 39 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations.
Across 132 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$437
- Tempus AI, Inc$250
- Sanofi$201
- AstraZeneca$190
- Pharmacyclics LLC, An Abbvie Company$172
- Bristol Myers Squibb$129
- plus $1K from 33 others
What the payments were for
- Consulting fees$2509%
- Food & beverage$2,51890%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 23 | $437 |
| Tempus AI, Inc | 1 | $250 |
| Sanofi | 10 | $201 |
| AstraZeneca(2 entities) | 8 | $190 |
| Pharmacyclics LLC, An Abbvie Company | 10 | $172 |
| Bristol Myers Squibb | 7 | $129 |
| Galvanize Therapeutics, Inc | 1 | $116 |
| Amgen | 6 | $112 |
| Daiichi Sankyo Inc. | 5 | $106 |
| Regeneron Healthcare Solutions, Inc. | 6 | $105 |
| Eisai Inc. | 4 | $85 |
| Pfizer | 5 | $78 |
| Gilead | 5 | $78 |
| Merck | 4 | $71 |
| AVEO Pharmaceuticals, Inc. | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 4 | $57 |
| GSK | 3 | $54 |
| Johnson & Johnson | 2 | $36 |
| Genentech USA, Inc. | 2 | $34 |
| Astellas Pharma US Inc | 2 | $33 |
| Rigel Pharmaceuticals, Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $32 |
| AbbVie | 1 | $30 |
| Sirtex Medical Inc | 1 | $30 |
| Pharmaessentia USA Corporation | 1 | $28 |
| EMD Serono, Inc. | 1 | $24 |
| Incyte Corporation | 1 | $24 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| CTI Biopharma Corp. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Array Biopharma Inc | 1 | $16 |
| Deciphera Pharmaceuticals Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALIYA SYSTEM$116
How this compares
$2,813 in reported general payments places this provider in the 55th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 23 | $454,669 |
| BrukinsaZanubrutinib | 29 | $433,672 |
| TagrissoOsimertinib Mesylate | 25 | $422,917 |
| ImbruvicaIbrutinib | 24 | $369,537 |
| Lenalidomide | 33 | $265,225 |
| TasignaNilotinib Hcl | 12 | $236,649 |
| EliquisApixaban | 118 | $113,548 |
| XareltoRivaroxaban | 131 | $106,507 |
| Abiraterone Acetate | 22 | $21,601 |
| Potassium Chloride | 87 | $2,461 |
| Imatinib Mesylate | 12 | $2,048 |
| Morphine Sulfate ErMorphine Sulfate | 91 | $1,783 |
| Letrozole | 103 | $1,532 |
| Oxycodone Hcl | 95 | $1,520 |
| Hydroxyurea | 36 | $1,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $129 | $454,66923 claims |
| AstraZenecaTagrisso | $190 | $422,91725 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $172 | $369,53724 claims |
| NovartisTasigna | $437 | $236,64912 claims |
| PfizerEliquis | $78 | $113,548118 claims |
| Johnson & JohnsonXarelto | $36 | $106,507131 claims |
| Lilly USA, LLCOlanzapine | $32 | $39128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Lawrenceburg
- Costantine AlbanyLafayette$212K
- Sunil BabuFort Wayne$166K
- Natraj AmmakkanavarIndianapolis$129K
- Rafat AnsariMishawaka$90K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
- Eduardo BraunWestville$39K
- Daniel SonnenburgIndianapolis$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.